• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Am Coll Cardiol . Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review

tetano

Editor, Senior Moderator
J Am Coll Cardiol


. 2021 Oct 19;78(16):1635-1654.
doi: 10.1016/j.jacc.2021.08.021.
Investigating Lipid-Modulating Agents for Prevention or Treatment of COVID-19: JACC State-of-the-Art Review


Azita H Talasaz[SUP] 1 [/SUP], Parham Sadeghipour[SUP] 2 [/SUP], Maryam Aghakouchakzadeh[SUP] 3 [/SUP], Isaac Dreyfus[SUP] 4 [/SUP], Hessam Kakavand[SUP] 3 [/SUP], Hamid Ariannejad[SUP] 5 [/SUP], Aakriti Gupta[SUP] 6 [/SUP], Mahesh V Madhavan[SUP] 7 [/SUP], Benjamin W Van Tassell[SUP] 8 [/SUP], David Jimenez[SUP] 9 [/SUP], Manuel Monreal[SUP] 10 [/SUP], Muthiah Vaduganathan[SUP] 11 [/SUP], John Fanikos[SUP] 12 [/SUP], Dave L Dixon[SUP] 8 [/SUP], Gregory Piazza[SUP] 11 [/SUP], Sahil A Parikh[SUP] 7 [/SUP], Deepak L Bhatt[SUP] 11 [/SUP], Gregory Y H Lip[SUP] 13 [/SUP], Gregg W Stone[SUP] 14 [/SUP], Harlan M Krumholz[SUP] 15 [/SUP], Peter Libby[SUP] 11 [/SUP], Samuel Z Goldhaber[SUP] 11 [/SUP], Behnood Bikdeli[SUP] 16 [/SUP]



Affiliations

Abstract

Coronavirus disease-2019 (COVID-19) is associated with systemic inflammation, endothelial activation, and multiorgan manifestations. Lipid-modulating agents may be useful in treating patients with COVID-19. These agents may inhibit viral entry by lipid raft disruption or ameliorate the inflammatory response and endothelial activation. In addition, dyslipidemia with lower high-density lipoprotein cholesterol and higher triglyceride levels portend worse outcomes in patients with COVID-19. Upon a systematic search, 40 randomized controlled trials (RCTs) with lipid-modulating agents were identified, including 17 statin trials, 14 omega-3 fatty acids RCTs, 3 fibrate RCTs, 5 niacin RCTs, and 1 dalcetrapib RCT for the management or prevention of COVID-19. From these 40 RCTs, only 2 have reported preliminary results, and most others are ongoing. This paper summarizes the ongoing or completed RCTs of lipid-modulating agents in COVID-19 and the implications of these trials for patient management.

Keywords: COVID-19; fibrate; lipid-modulating agent; niacin; omega-3; statin.
 
Back
Top Bottom